Navigation Links
HealthCare, Technology Briefing: Market Movers for the Week - Technologies-Scan Corp, GNC, Galena Biopharma, Immunomedics, Amarin
Date:8/26/2013

ment of cancer, autoimmune and other serious diseases, reported financial results for the fourth quarter and fiscal year ended June 30, 2013. The Company also highlighted recent key developments and planned activities for its clinical pipeline.  To read the Fourth Quarter Fiscal 2013 Results go to http://finance.yahoo.com/news/immunomedics-announces-fiscal-2013-results-200000249.html

Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.  Vascepa[(R)] (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription.  AMRN closed up 9cents per share on Friday (August 23, 2013) on over 3.9Million shares traded.

Microsoft Corp. (NASDAQ: MSFT) is expected remain in the spotlight on Monday as investors assess whether to extend the Ballmer bounce -- the best one-day gain in four years on the news CEO Steve Ballmer planned to retire.  Read the full article at http://www.marketwatch.com/story/microsoft-is-mondays-stock-to-watch-2013-08-24?siteid=yhoof2.

FinancialNewsMedia.com  is leading provider of third party publishing & 

SOURCE FN Media Group LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sterilization Market (Medical Devices, Pharmaceutical, Healthcare, Food Applications), Equipments & Contract Services - Global Forecast To 2017
2. Nanotechnologies and bio-inspiration for healthcare, communication, more will highlight SPIE Microtechnologies
3. GNS Healthcare, Dana-Farber and Mount Sinai Collaborate to Build Computer Model of Multiple Myeloma
4. Healthcare, Regulatory and Reimbursement Landscape - Australia
5. Bayer CropScience and MS Technologies Receive Approval for Balance GT Soybean Technology in the United States
6. ACRES Launches Global Clinical Research Network Technology Platform
7. American Museum of Agriculture Changes Name to Reflect Bayer CropScience’s Agriculture Tradition and World-Class Technology
8. Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix, Puma Biotechnology, and Halozyme
9. Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
10. Easy, Reliable Viscosity Measurements via Viscometer-Rheometer-on-a-Chip (VROC) Technology
11. Biotech & BioPharma Professionals: CA Board of Pharmacy Executive, Virginia Herold, to Deliver Keynote at BSMA Annual Biotechnology Conference Oct 8-9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... brain can form insulin-producing cells that mimic those missing ... in the April 26 issue of PLoS Medicine. , ... patients, Seung Kim, MD, PhD, the lead author and ... School of Medicine, said it could lead to new ...
... Chicago have found that a recently discovered biological process known ... in the nucleus -- also occurs near the cell's surface ... of proteins, providing a novel target for the development of ... 2005 issue of the journal Cell, answers a question dating ...
... first field trial of plants genetically tweaked to absorb ... beat out their wild-type counterparts. The results raised hopes ... cleaning up polluted soil. , The new research findings, ... Technology, show that three transgenic lines of the Indian ...
Cached Biology News:Stem cells from brain transformed to produce insulin at Stanford 2Stem cells from brain transformed to produce insulin at Stanford 350-year-old Mystery Solved: Protein Tags Regulate Key Ion Channel 250-year-old Mystery Solved: Protein Tags Regulate Key Ion Channel 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4